Medinice (ICE) Stock Overview
A medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ICE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medinice S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł55.00 |
| 52 Week High | zł65.30 |
| 52 Week Low | zł6.74 |
| Beta | 1.11 |
| 1 Month Change | 35.80% |
| 3 Month Change | 258.07% |
| 1 Year Change | 587.50% |
| 3 Year Change | 220.14% |
| 5 Year Change | 62.72% |
| Change since IPO | 409.26% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Medinice's (WSE:ICE) Cash Burn Rate
Apr 04
We Think You Should Be Aware Of Some Concerning Factors In Medinice's (WSE:ICE) Earnings
Apr 02Will Medinice (WSE:ICE) Spend Its Cash Wisely?
Jul 29Here's Why We're Not Too Worried About Medinice's (WSE:ICE) Cash Burn Situation
Jun 27We're Hopeful That Medinice (WSE:ICE) Will Use Its Cash Wisely
Dec 30Shareholder Returns
| ICE | PL Medical Equipment | PL Market | |
|---|---|---|---|
| 7D | 3.8% | -1.8% | 5.7% |
| 1Y | 587.5% | 25.6% | 33.4% |
Return vs Industry: ICE exceeded the Polish Medical Equipment industry which returned 22.8% over the past year.
Return vs Market: ICE exceeded the Polish Market which returned 32.8% over the past year.
Price Volatility
| ICE volatility | |
|---|---|
| ICE Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 10.8% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: ICE's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: ICE's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Sanjeev Choudhary | www.medinice.pl |
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium; and AtriClamp, a clip designed to close the left atrial appendage to minimize the risk of stroke in patients with atrial fibrillation. It also provides MiniMax, an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart’s conduction system; and EP Bioptom, an electrode for endomyocardial biopsy using 3D mapping enabling simultaneous biopsy and creation of a three-dimensional heart map.
Medinice S.A. Fundamentals Summary
| ICE fundamental statistics | |
|---|---|
| Market cap | zł510.77m |
| Earnings (TTM) | -zł6.72m |
| Revenue (TTM) | n/a |
Is ICE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICE income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł166.00k |
| Gross Profit | -zł166.00k |
| Other Expenses | zł6.56m |
| Earnings | -zł6.72m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 08, 2026
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ICE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 15:49 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medinice S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.